Sub Subramony, M.D., discusses how the modified Friedreich Ataxia Rating Scale (mFARS) is valuable for monitoring disease progression in clinical trials and its applicability in everyday clinical practice for assessing patient status.
Video content above is prompted by the following:
The modified Friedreich Ataxia Rating Scale (mFARS) has been developed to monitor FA disease progression in clinical trials. Is mFARS useful in your everyday clinical practice?
WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
September 26th 2024In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Read More
Cycling Training Shows Protective Effects on Gait, Balance in DMD
August 22nd 2024Both cycling and home-based exercise training helped maintain gait and balance parameters in children with Duchenne muscular dystrophy (DMD), with cycling training also improving antero-posterior balance.
Read More